Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

16/09/2015 - 2 minutes

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy.


Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand Pharma, who licensed out the drug to Sanofi for development as a once-per-day injection of a prandial GLP-1 agonist (which stimulates an increase in insulin secretion, lowering blood glucose). However, competition of Lixisenatide side-project was already fierce, with Victoza by Novo Nordisk already being a super-GLP-1-agonist blockbuster. Novo continues to plod on in its pursuit of global diabetes domination against Sanofi, particularly motivated in the lead up to World Diabetes Day.

Lantus, on the other hand, is the long-acting insulin glargine analog giant, also administered once daily to lower blood glucose. Previously unrivaled, Lantus has dominated the market for years, earning Sanofi up to €6.2Bn last year in revenue. However, since the Lantus patent expired in February of this year,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member